Design Therapeutics reports Q3 net loss $17.7M; cash $344.2M; DT-216 Phase 1 SAD data in Dec 2022

Design Therapeutics, Inc.

2022-Q3 EPS reported -$0.83

Net loss of $17.7M for Q3 2022; R&D expenses $14.3M, G&A expenses $4.9M.
Cash, equivalents and securities of $344.2M as of Sept 30, 2022, supporting multi-year runway.
Initial data from DT-216 single-ascending dose Phase 1 for Friedreich Ataxia expected Dec 2022.
Multiple-ascending dose Phase 1 dosing initiated; completion anticipated mid-2023.
DM1 GeneTAC program preclinical; clinical development expected to begin in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Design Therapeutics, Inc. reported third quarter 2022 results: net income Net loss was $17.7 million.

Period: third quarter 2022
Net income: Net loss was $17.7 million
Result: reported results

Exact text from the filing

Design Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Design Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-021862

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.